KKR Injects $60M In Slayback Pharma
By Matthew Perlman ( January 6, 2017, 1:03 PM EST) -- Pharmaceutical research and development company Slayback Pharma LLC said Thursday that it has received a $60 million investment from private equity giant KKR & Co. to help accelerate the development of its portfolio of complex generic drugs....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.